Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.

Knelson EH, Gaviglio AL, Tewari AK, Armstrong MB, Mythreye K, Blobe GC.

J Clin Invest. 2013 Nov;123(11):4786-98.

2.

Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.

Knelson EH, Gaviglio AL, Nee JC, Starr MD, Nixon AB, Marcus SG, Blobe GC.

J Clin Invest. 2014 Jul;124(7):3016-31. doi: 10.1172/JCI74270. Epub 2014 Jun 17.

3.

Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.

Hempel N, How T, Cooper SJ, Green TR, Dong M, Copland JA, Wood CG, Blobe GC.

Carcinogenesis. 2008 May;29(5):905-12. doi: 10.1093/carcin/bgn049. Epub 2008 Feb 24.

4.

Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.

Henriksen JR, Haug BH, Buechner J, Tømte E, Løkke C, Flaegstad T, Einvik C.

BMC Dev Biol. 2011 Jan 3;11:1. doi: 10.1186/1471-213X-11-1.

5.

MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.

Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH.

Biochem Biophys Res Commun. 2006 Dec 8;351(1):192-7. Epub 2006 Oct 12.

6.

MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.

Lovén J, Zinin N, Wahlström T, Müller I, Brodin P, Fredlund E, Ribacke U, Pivarcsi A, Påhlman S, Henriksson M.

Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1553-8. doi: 10.1073/pnas.0913517107. Epub 2010 Jan 4.

7.

Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.

Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME, Molenaar JJ, van Nes J, Versteeg R.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19190-5. doi: 10.1073/pnas.1208215109. Epub 2012 Oct 22.

8.

p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.

Dreidax D, Bannert S, Henrich KO, Schröder C, Bender S, Oakes CC, Lindner S, Schulte JH, Duffy D, Schwarzl T, Saadati M, Ehemann V, Benner A, Pfister S, Fischer M, Westermann F.

Hum Mol Genet. 2014 Dec 20;23(25):6826-37. doi: 10.1093/hmg/ddu406. Epub 2014 Aug 7.

PMID:
25104850
9.

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA.

Oncogene. 2010 May 20;29(20):2905-15. doi: 10.1038/onc.2010.64. Epub 2010 Mar 8.

10.

Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.

Akter J, Takatori A, Hossain MS, Ozaki T, Nakazawa A, Ohira M, Suenaga Y, Nakagawara A.

Clin Cancer Res. 2011 Nov 1;17(21):6681-92. doi: 10.1158/1078-0432.CCR-11-0313. Epub 2011 Sep 9.

11.

NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.

Hossain S, Takatori A, Nakamura Y, Suenaga Y, Kamijo T, Nakagawara A.

Cancer Res. 2012 Sep 1;72(17):4587-96. doi: 10.1158/0008-5472.CAN-12-0943. Epub 2012 Jul 19.

12.

The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer.

Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC.

Cancer Res. 2007 Feb 1;67(3):1090-8.

13.

Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.

Ikram F, Ackermann S, Kahlert Y, Volland R, Roels F, Engesser A, Hertwig F, Kocak H, Hero B, Dreidax D, Henrich KO, Berthold F, Nürnberg P, Westermann F, Fischer M.

Mol Oncol. 2016 Feb;10(2):344-59. doi: 10.1016/j.molonc.2015.10.020. Epub 2015 Nov 7.

14.

Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas.

Suzuki T, Bogenmann E, Shimada H, Stram D, Seeger RC.

J Natl Cancer Inst. 1993 Mar 3;85(5):377-84.

PMID:
8433391
15.

Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.

Chevrier L, Meunier AC, Cochaud S, Muller JM, Chadéneau C.

Int J Oncol. 2008 Nov;33(5):1081-9.

PMID:
18949372
16.

Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.

Gatza CE, Holtzhausen A, Kirkbride KC, Morton A, Gatza ML, Datto MB, Blobe GC.

Neoplasia. 2011 Aug;13(8):758-70.

17.

Transforming growth factor beta receptor type III is a tumor promoter in mesenchymal-stem like triple negative breast cancer.

Jovanović B, Beeler JS, Pickup MW, Chytil A, Gorska AE, Ashby WJ, Lehmann BD, Zijlstra A, Pietenpol JA, Moses HL.

Breast Cancer Res. 2014 Jul 1;16(4):R69. doi: 10.1186/bcr3684.

18.

GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.

Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T, Kopp-Schneider A, Opitz L, Capper D, von Deimling A, Wiegand I, Milde T, Mahlknecht U, Westermann F, Popanda O, Roels F, Hero B, Berthold F, Fischer M, Kulozik AE, Witt O, Deubzer HE.

Cancer Res. 2014 May 1;74(9):2604-16. doi: 10.1158/0008-5472.CAN-13-1904. Epub 2014 Jan 13.

19.

Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.

Koppen A, Ait-Aissa R, Hopman S, Koster J, Haneveld F, Versteeg R, Valentijn LJ.

Cancer Lett. 2007 Oct 28;256(2):218-28. Epub 2007 Jul 23.

PMID:
17643814
20.

Induction of Id-1 by FGF-2 involves activity of EGR-1 and sensitizes neuroblastoma cells to cell death.

Passiatore G, Gentilella A, Rom S, Pacifici M, Bergonzini V, Peruzzi F.

J Cell Physiol. 2011 Jul;226(7):1763-70. doi: 10.1002/jcp.22505.

Supplemental Content

Support Center